Clinical Trial Update: Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immune responses of the GSK 257049 vaccine in infants living in a malaria-endemic region; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• GSK 257049

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2013-01-18